Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J de Knegt

Showing results (1-10 of 200) with videos related to

Pageof 20
Sort By:
Scandinavian Journal of Gastroenterology. Supplement|June 20, 2006
Current therapy of hepatitis CRobert J de Knegt
Transplant International : Official Journal of the European Society for Organ Transplantation|June 4, 2016
HCV treatment in liver transplantation: timing is the challengeRobert J De Knegt
Scandinavian Journal of Gastroenterology. Supplement|June 20, 2006
Non-invasive measurement of liver fibrosis: application of the FibroScan in hepatologyClaudia Verveer, Robert J de Knegt
Hepatology (Baltimore, Md.)|May 25, 2002
Long-term effect of treatment of acute Budd-Chiari syndrome with a transjugular intrahepatic portosytemic shuntHans Blokzijl, Robert J de Knegt
Alimentary Pharmacology & Therapeutics|December 19, 2019
Editorial: rapid disease progression in hepatitis delta-can we turn the tide?Milan J Sonneveld, Robert J de Knegt
Alimentary Pharmacology & Therapeutics|November 5, 2024
Editorial: Navigating the Beta-Blocker Dilemma in Advanced Liver Cirrhosis-When Is the Right Time to Discontinue?Louise J M Alferink, Robert J de Knegt
Hepatology Communications|May 20, 2022
Reply to: "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD"Laurens A van Kleef, Robert J de Knegt
Hepatology (Baltimore, Md.)|September 16, 2022
Modifiable risk factors for fatty liver disease: Time to actLaurens A van Kleef, Robert J de Knegt
Hepatology (Baltimore, Md.)|May 3, 2022
The transition from NAFLD to MAFLD: One size still does not fit all-Time for a tailored approach?Laurens A van Kleef, Robert J de Knegt
Transplantation|January 4, 2017
The Path to Cancer and Back: Immune Modulation During Hepatitis C Virus Infection, Progression to Fibrosis and Cancer, and Unexpected Roles of New AntiviralsJose D Debes, Robert J de Knegt, Andre Boonstra
Pageof 20

Showing results (1-10 of 200) with videos related to

Sort By:
Pageof 20
Scandinavian Journal of Gastroenterology. Supplement|June 20, 2006
Current therapy of hepatitis CRobert J de Knegt
Transplant International : Official Journal of the European Society for Organ Transplantation|June 4, 2016
HCV treatment in liver transplantation: timing is the challengeRobert J De Knegt
Scandinavian Journal of Gastroenterology. Supplement|June 20, 2006
Non-invasive measurement of liver fibrosis: application of the FibroScan in hepatologyClaudia Verveer, Robert J de Knegt
Hepatology (Baltimore, Md.)|May 25, 2002
Long-term effect of treatment of acute Budd-Chiari syndrome with a transjugular intrahepatic portosytemic shuntHans Blokzijl, Robert J de Knegt
Alimentary Pharmacology & Therapeutics|December 19, 2019
Editorial: rapid disease progression in hepatitis delta-can we turn the tide?Milan J Sonneveld, Robert J de Knegt
Alimentary Pharmacology & Therapeutics|November 5, 2024
Editorial: Navigating the Beta-Blocker Dilemma in Advanced Liver Cirrhosis-When Is the Right Time to Discontinue?Louise J M Alferink, Robert J de Knegt
Hepatology Communications|May 20, 2022
Reply to: "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD"Laurens A van Kleef, Robert J de Knegt
Hepatology (Baltimore, Md.)|September 16, 2022
Modifiable risk factors for fatty liver disease: Time to actLaurens A van Kleef, Robert J de Knegt
Hepatology (Baltimore, Md.)|May 3, 2022
The transition from NAFLD to MAFLD: One size still does not fit all-Time for a tailored approach?Laurens A van Kleef, Robert J de Knegt
Transplantation|January 4, 2017
The Path to Cancer and Back: Immune Modulation During Hepatitis C Virus Infection, Progression to Fibrosis and Cancer, and Unexpected Roles of New AntiviralsJose D Debes, Robert J de Knegt, Andre Boonstra
Pageof 20